Join us on Wednesday, August 2^nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Genentech, a member of the Roche Group, Genmab US Inc, and Regeneron Pharmaceuticals Inc.

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise the scientific rationale for the evaluation of CD20 × CD3 bispecific antibodies for various forms of non-Hodgkin lymphoma, and assess the similarities and differences between currently available and investigational agents in this class.
• Evaluate available findings with CD20 × CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL), and identify patients for whom treatment with this novel approach should be considered and/or recommended.
• Develop an understanding of the current clinical research database with CD20 × CD3 bispecific antibodies for the management of R/R diffuse large B-cell lymphoma (DLBCL) in preparation for the potential availability of these agents.
• Recognize adverse events associated with available and investigational CD20 × CD3 bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing studies evaluating promising CD20 x CD3 bispecific antibody-based strategies for FL and DLBCL, and counsel appropriate patients regarding potential clinical trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Hutchings — Advisory Committee: AbbVie Inc, Janssen Biotech Inc, Merck, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Janssen Biotech Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Merck, Novartis, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc. Dr Nastoupil — Advisory Committee: Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Incyte Corporation; Contracted Research: Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

SURVEY PARTICIPANTS — Jeremy S Abramson, MD, MMSc — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Cellectar Biosciences Inc, Century Therapeutics, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Interius BioTherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Seagen Inc. Brad S Kahl, MD — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics,AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Novartis, Roche Laboratories Inc. Matthew Matasar, MD — No relevant conflicts of interest to disclose. Tycel Phillips, MD — Advisory Committee: AbbVie Inc, ADC Therapeutics, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Seagen Inc, Xencor; Consulting Agreements: BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Merck; Contracted Research: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, Genmab US Inc, and Regeneron Pharmaceuticals Inc.